Files and links (2)
Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents A Systematic Review and Meta-Analysis1.27 MB
Published VersionCC BY V4.0, Open Access
Journal article
Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis
Vaccines, Vol.10(11), pp.1-14
2022
PMID: 36366387
Appears in COVID-19 Research
Abstract
Efforts to control the COVID-19 pandemic have expanded to the vaccination of children and adolescents. This systematic review assesses the utility of the BNT162b2 (Pfizer-BioNTech) vaccine in children and adolescents aged 5-18 years, considering its effectiveness against COVID infection, hospital and intensive care admission and duration of effectiveness after vaccination. Six databases were searched following the PRISMA guidelines. Pooled estimates and 95% confidence intervals (CIs) were calculated using meta-analysis. Fifteen studies were included in the systematic review, while 12 studies were included in the meta-analysis. Evidence suggests that the two-dose vaccination regime provided high effectiveness of 92% (95% CI, 86-96) against COVID infection. Vaccination also conferred high protection against hospitalisation (91%) and intensive care admission (85%). The vaccine was highly protective against the Delta variant of the virus, but showed a lower protection against the Omicron variant. Most adverse effects were transient and mild, commonly including pain at the injection site, fatigue and headache. Current findings are suggestive of waning immunity over time; however, further research is needed to investigate the relevance of booster doses in this age group. In summary, the Pfizer-BioNTech BNT162b2 vaccine demonstrated high levels of protection against COVID-19 infection and its complications while maintaining an adequate safety profile in children and adolescents.
Details
- Title
- Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis
- Authors
- Jewel Maria Sabu (Author) - James Cook UniversityIzza Zahid (Author) - James Cook UniversityNamitha Jacob (Author) - James Cook UniversityFaith O. O. Alele (Author) - James Cook UniversityBunmi S. S. Malau-Aduli (Corresponding Author) - James Cook University
- Publication details
- Vaccines, Vol.10(11), pp.1-14
- Publisher
- MDPI AG
- Date published
- 2022
- DOI
- 10.3390/vaccines10111880
- ISSN
- 2076-393X
- PMID
- 36366387
- Copyright note
- © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- Data Availability
- All data generated from the study have been included in the manuscript. Data were obtained from the primary studies included in the review.
- Organisation Unit
- School of Health - Public Health
- Language
- English
- Record Identifier
- 99967696702621
- Output Type
- Journal article
Metrics
3 File views/ downloads
73 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Web Of Science research areas
- Immunology
- Medicine, Research & Experimental
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites